Faculty

Needs Statement

Substance use disorder (SUD) is a treatable, chronic disease that often involves cycles of relapse and remission due to complex interactions in the brain, heredities, and an individual’s environment layered with life experiences. People with SUD often engage in risky and compulsive behaviors that result in harm to themselves or others. An individual’s substance use treatment and services plan must be assessed continually and modified as necessary to ensure that it meets his or her changing needs. This can become quite complex as many drug-addicted individuals often have other co-morbidities that complicate care, including mental health disorders. As a result, several challenges can arise from the comprehensive care of substance use disorders. This warrants the need for best practices and effective communication between providers and their patients regarding individualized assessments and treatment plans that they can collaboratively develop and agree upon together. These met needs should yield treatment and support services that also consider and reflect each patient’s individual needs and preferences.

Target Audience

Healthcare professionals in a primary care setting.

Objectives

Upon completion of this educational activity, learners will be able to:
1. Review monitoring and documentation strategies for substance use disorder treatment.
2. Outline key components to communicate with a patient about substance use disorder.
3. Discuss practical strategies for motivating a patient’s commitment to treatment goals.
4. Describe the process of shared decision making with patients.

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 2.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0521-H1.0-UK15C

CPE
This knowledge-based activity will award 2.00 contact hours (0.200 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Other
UK Healthcare CECentral certifies this activity for 2.00 hours of participation.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 2.00 clinical continuing education credits.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.00 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

The activity was supported by Anthem.